Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/ER4 stock hub

FRA/ER4 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/ER4is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

416.4M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/ER4FRA/ER4

—

Loading chart…

In the news

Latest news · FRA/ER4

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-1.6

P25 n/aP50 n/aP75 n/a

ROIC-20

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/ER4 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

194

Groups with data

Currency

USD

Showing 194 of 194 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	900
Employees Change	-700%
Employees Change Percent	-43.75
Enterprise value	EUR 776.9M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 416.4M
Price	EUR 7.74
Price currency	EUR
Rev Per Employee	652,209.6x
Sic	2836
Symbol	fra/ER4
Website	https://www.emergentbiosolutions.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.79%
EV Earnings	-104.16x
EV/EBIT	12.14x
EV/EBITDA	5.49x
EV/FCF	6.62x
EV/Sales	1.35x
FCF yield	28.2%
P/B ratio	0.92x
P/S ratio	0.71x
PE Ratio10 Y	46.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.13%
EBITDA Margin	24.63%
FCF margin	20.01%
Gross margin	47.49%
Gross Profit	EUR 278.8M
Gross Profit Growth	10.67%
Gross Profit Growth Q	-38.38%
Gross Profit Growth3 Y	26.15%
Gross Profit Growth5 Y	-19.93%
Net Income	EUR -7.5M
Net Income Growth Q	-90%
Pretax Margin	0.52%
Profit Margin	-1.27%
Profit Per Employee	EUR -8,288
ROA	3.43
Roa5y	1.02
ROCE	6.43
ROE	-1.6
Roe5y	-19.53
ROIC	-20.02
Roic5y	0.76

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-13.33%
Cagr15y	-4.3%
Cagr1y	84.72%
Cagr3y	0.57%
Cagr5y	-31.28%
EPS Growth Q	-93.75
FCF Growth	43.43%
FCF Growth5 Y	-15.29%
OCF Growth	34.42%
OCF Growth10 Y	-0.3%
OCF Growth5 Y	-21.08%
Revenue Growth	-29.89x
Revenue Growth Q	-29.75x
Revenue Growth3 Y	-11.44x
Revenue Growth5 Y	-16.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.49
Assets	EUR 1.1B
Cash	EUR 139M
Current Assets	EUR 540.7M
Current Liabilities	EUR 126.1M
Debt	EUR 507M
Debt EBITDA	EUR 3.51
Debt Equity	EUR 1.12
Debt FCF	EUR 4.32
Equity	EUR 453.7M
Interest Coverage	1.35
Liabilities	EUR 691.5M
Long Term Assets	EUR 604.5M
Long Term Liabilities	EUR 565.4M
Net Cash	EUR -368M
Net Cash By Market Cap	EUR -88.37
Net Debt EBITDA	EUR 2.55
Net Debt Equity	EUR 0.81
Net Debt FCF	EUR 3.13
Tangible Book Value	EUR 45.7M
Tangible Book Value Per Share	EUR 0.88

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.29
Inventory Turnover	1.11
Net Working Capital	EUR 287.1M
Quick ratio	1.9
Working Capital	EUR 424M
Working Capital Turnover	EUR 1.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.26%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-76.09%
1Y total return	84.64%
200-day SMA	8.16
3Y total return	1.71%
50-day SMA	7.19
50-day SMA vs 200-day SMA	50under200
5Y total return	-84.67%
All Time High	115
All Time High Change	-93.27%
All Time High Date	2020-08-06
All Time Low	1.38
All Time Low Change	462.09%
All Time Low Date	2024-02-21
ATR	0.18
Ch YTD	-24.6
High	7.74
High52	11.72
High52 Date	2026-01-08
High52ch	-33.96%
Low	7.74
Low52	4.77
Low52 Date	2025-05-08
Low52ch	84.64%
Ma50ch	7.62%
Price vs 200-day SMA	-5.18%
RSI	61.23
RSI Monthly	47.2
RSI Weekly	47.94
Sharpe ratio	0.82x
Sortino ratio	1.53
Total Return	1.26%
Tr YTD	-24.6
Tr15y	-48.26%
Tr1m	11.93%
Tr1w	7.95%
Tr3m	-12.26%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 65.3M
Operating Income Growth Q	-79.17
Operating Income Growth5 Y	-34.02
Operating margin	11.13

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46,949,865%
Net Borrowing	-95,395,725
Shares Insiders	2%
Shares Institutions	80.54%
Shares Qo Q	7.82%
Shares Yo Y	-1.26%
Short Ratio	11.17

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 103M
Average Volume	75.35x
Bv Per Share	8.76
CAPEX	EUR -10.9M
Ch10y	-76.09
Ch15y	-48.26
Ch1m	11.93
Ch1w	7.95
Ch1y	84.64
Ch3m	-12.26
Ch3y	1.71
Ch5y	-84.67
Ch6m	-12.22
Change	0.78%
Change From Open	0
Close	7.68
Days Gap	0.78
Depreciation Amortization	77,503,726.8
Earnings Date	2026-04-30
EBIT	EUR 65.3M
EBITDA	EUR 144.6M
EPS	EUR -0.18
F Score	5
FCF	EUR 117.4M
FCF EV Yield	15.11x
Financing CF	-128,013,480
Fiscal Year End	December
Founded	1,998
Income Tax	EUR 10.5M
Investing CF	6,504,750
Is Primary Listing	0
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Ma150	8.62
Ma150ch	-10.18%
Ma20	7.15
Ma20ch	8.24%
Net CF	7,545,510
Next Earnings Date	2026-08-03
Open	7.74
P FCF Ratio	3.55
P OCF Ratio	3.24
Ppne	177,478,446.6
Price Date	2026-05-08
Price EBITDA	EUR 2.88
Ptbv Ratio	9.11
Relative Volume	9.71x
Revenue	586,988,640x
SBC By Revenue	2.45x
Share Based Comp	14,397,180
Tax By Revenue	1.79x
Tax Rate	345.71%
Tr6m	-12.22%
Volume	0
Z Score	1.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/ER4 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/ER4 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/ER4?

Insider, institutional, and short-interest positioning.

Institutional ownership

+80.5%

Share of float held by funds and institutions

Insider ownership

+2.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/ER4 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

61.2

Neutral momentum band

Price vs 200-day MA

-5.2%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.82

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/ER4

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/ER4 stock rating?

fra/ER4 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/ER4 analysis?

The full report lives at /stocks/fra/ER4/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/ER4?

The latest report frames fra/ER4 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/ER4 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.